抗甲亢药物致粒细胞缺乏症11例临床分析  

Clinical analysis of 11 cases of agranulocytosis induced by antithyroid drugs

作　　者：曾文谊[1] 林颖[1] 李军[1] 陈莉[1] 黄妙婵[1] 

机构地区：[1]广东省东莞市人民医院临床药学科,广东东莞523018

出　　处：《中国药物经济学》2013年第3期151-152,共2页China Journal of Pharmaceutical Economics

摘　　要：目的探讨抗甲状腺药物(ATD)致粒细胞缺乏症的作用机制,提高诊治水平。方法对抗甲状腺药物致11例粒细胞缺乏症的临床资料进行分析。结果 ATD引起粒细胞缺乏症多发生于初始治疗的最初2～3个月或再次用药的1～2个月。采取停用ATD,使用粒细胞集落刺激因子(G-CSF)、广谱抗生素、消毒隔离等综合治疗,效果明显。结论接受ATD治疗患者,若治疗中出现发热、咽痛、全身不适等症状时立即查白细胞,以及时发现粒细胞缺乏的发生。Objective To investigate the mechanism induced granulocyte cell deficiency antithyroid drug （ATD）, to improve the diagnosis and treatment. Methods Against thyroid drugs caused analyzed the clinical data of 11 patients with myeloid deficiency. Results ATD-induced agranulocytosis the disease mostly occurs in the initial treatment of the first 2-3 months or 1-2 months medication again. Comprehensive treatment using disable ATD; granulocyte colony-stimulating factor （G-CSF）, broad-spectrum antibiotics, disinfection and isolation, the effect is obvious. Conclusion Accept the ATD patients treated immediately check white blood cells in the treatment symptoms of fever, sore throat,general malaise, and found that the incidence of agranulocytosis.

关 键 词：甲状腺功能亢进症 粒细胞缺乏症 ATD 不良反应 

分 类 号：R581.1[医药卫生—内分泌]